History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium

Albina N Minlikeeva; Jo L Freudenheim; Rikki A Cannioto; J Brian Szender; Kevin H Eng; Francesmary Modugno; Roberta B Ness; Michael J LaMonte; Grace Friel; Brahm H Segal; Kunle Odunsi; Paul Mayor; Emese Zsiros; Barbara Schmalfeldt; Rüdiger Klapdor; Thilo Dӧrk; Peter Hillemanns; Linda E Kelemen; Martin Kӧbel; Helen Steed; Anna de Fazio; Susan J Jordan; Christina M Nagle; Harvey A Risch; Mary Anne Rossing; Jennifer A Doherty; Marc T Goodman; Robert Edwards; Keitaro Matsuo; Mika Mizuno; Beth Y Karlan; Susanne K Kjær; Estrid Høgdall; Allan Jensen; Joellen M Schildkraut; Kathryn L Terry; Daniel W Cramer; Elisa V Bandera; Lisa E Paddock; Lambertus A Kiemeney; Leon F Massuger; Jolanta Kupryjanczyk; Andrew Berchuck; Jenny Chang-Claude; Brenda Diergaarde; Penelope M Webb; Kirsten B Moysich; Australian Ovarian Cancer Study Group

doi:10.1007/s10552-017-0867-1

History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium

Albina N Minlikeeva, Jo L Freudenheim, Rikki A Cannioto, J Brian Szender, Kevin H Eng, Francesmary Modugno, Roberta B Ness, Michael J LaMonte, Grace Friel, Brahm H Segal, Kunle Odunsi, Paul Mayor, Emese Zsiros, Barbara Schmalfeldt, Rüdiger Klapdor, Thilo Dӧrk, Peter Hillemanns, Linda E Kelemen, Martin Kӧbel, Helen SteedAnna de Fazio, Susan J Jordan, Christina M Nagle, Harvey A Risch, Mary Anne Rossing, Jennifer A Doherty, Marc T Goodman, Robert Edwards, Keitaro Matsuo, Mika Mizuno, Beth Y Karlan, Susanne K Kjær, Estrid Høgdall, Allan Jensen, Joellen M Schildkraut, Kathryn L Terry, Daniel W Cramer, Elisa V Bandera, Lisa E Paddock, Lambertus A Kiemeney, Leon F Massuger, Jolanta Kupryjanczyk, Andrew Berchuck, Jenny Chang-Claude, Brenda Diergaarde, Penelope M Webb, Kirsten B Moysich, Australian Ovarian Cancer Study Group

Department of Clinical Medicine

17 Citations (Scopus)

Abstract

PURPOSE: Survival following ovarian cancer diagnosis is generally low; understanding factors related to prognosis could be important to optimize treatment. The role of previously diagnosed comorbidities and use of medications for those conditions in relation to prognosis for ovarian cancer patients has not been studied extensively, particularly according to histological subtype.

METHODS: Using pooled data from fifteen studies participating in the Ovarian Cancer Association Consortium, we examined the associations between history of hypertension, heart disease, diabetes, and medications taken for these conditions and overall survival (OS) and progression-free survival (PFS) among patients diagnosed with invasive epithelial ovarian carcinoma. We used Cox proportional hazards regression models adjusted for age and stage to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) overall and within strata of histological subtypes.

RESULTS: History of diabetes was associated with increased risk of mortality (n = 7,674; HR = 1.12; 95% CI = 1.01-1.25). No significant mortality associations were observed for hypertension (n = 6,482; HR = 0.95; 95% CI = 0.88-1.02) or heart disease (n = 4,252; HR = 1.05; 95% CI = 0.87-1.27). No association of these comorbidities was found with PFS in the overall study population. However, among patients with endometrioid tumors, hypertension was associated with lower risk of progression (n = 339, HR = 0.54; 95% CI = 0.35-0.84). Comorbidity was not associated with OS or PFS for any of the other histological subtypes. Ever use of beta blockers, oral antidiabetic medications, and insulin was associated with increased mortality, HR = 1.20; 95% CI = 1.03-1.40, HR = 1.28; 95% CI = 1.05-1.55, and HR = 1.63; 95% CI = 1.20-2.20, respectively. Ever use of diuretics was inversely associated with mortality, HR = 0.71; 95% CI = 0.53-0.94.

CONCLUSIONS: Histories of hypertension, diabetes, and use of diuretics, beta blockers, insulin, and oral antidiabetic medications may influence the survival of ovarian cancer patients. Understanding mechanisms for these observations could provide insight regarding treatment.

Original language	English
Journal	Cancer Causes & Control
Volume	28
Issue number	5
Pages (from-to)	469-486
ISSN	0957-5243
DOIs	https://doi.org/10.1007/s10552-017-0867-1
Publication status	Published - 1 May 2017

Keywords

Adrenergic beta-Antagonists/therapeutic use
Adult
Aged
Diabetes Mellitus/drug therapy
Disease-Free Survival
Female
Heart Diseases/complications
Humans
Hypertension/complications
Hypoglycemic Agents/therapeutic use
Insulin/therapeutic use
Middle Aged
Ovarian Neoplasms/complications
Risk
Survival Rate

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s10552-017-0867-1

http://europepmc.org/articles/pmc5500209?pdf=renderLicence: Unspecified

Cite this

Minlikeeva, A. N., Freudenheim, J. L., Cannioto, R. A., Szender, J. B., Eng, K. H., Modugno, F., Ness, R. B., LaMonte, M. J., Friel, G., Segal, B. H., Odunsi, K., Mayor, P., Zsiros, E., Schmalfeldt, B., Klapdor, R., Dӧrk, T., Hillemanns, P., Kelemen, L. E., Kӧbel, M., ... Australian Ovarian Cancer Study Group (2017). History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium. Cancer Causes & Control, 28(5), 469-486. https://doi.org/10.1007/s10552-017-0867-1

History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium. / Minlikeeva, Albina N; Freudenheim, Jo L; Cannioto, Rikki A et al.
In: Cancer Causes & Control, Vol. 28, No. 5, 01.05.2017, p. 469-486.

Research output: Contribution to journal › Journal article › Research › peer-review

Minlikeeva, AN, Freudenheim, JL, Cannioto, RA, Szender, JB, Eng, KH, Modugno, F, Ness, RB, LaMonte, MJ, Friel, G, Segal, BH, Odunsi, K, Mayor, P, Zsiros, E, Schmalfeldt, B, Klapdor, R, Dӧrk, T, Hillemanns, P, Kelemen, LE, Kӧbel, M, Steed, H, de Fazio, A, Jordan, SJ, Nagle, CM, Risch, HA, Rossing, MA, Doherty, JA, Goodman, MT, Edwards, R, Matsuo, K, Mizuno, M, Karlan, BY, Kjær, SK , Høgdall, E, Jensen, A, Schildkraut, JM, Terry, KL, Cramer, DW, Bandera, EV, Paddock, LE, Kiemeney, LA, Massuger, LF, Kupryjanczyk, J, Berchuck, A, Chang-Claude, J, Diergaarde, B, Webb, PM, Moysich, KB & Australian Ovarian Cancer Study Group 2017, 'History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium', Cancer Causes & Control, vol. 28, no. 5, pp. 469-486. https://doi.org/10.1007/s10552-017-0867-1

@article{d7eb2baa62a4497e9199ad510c9027da,

title = "History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium",

abstract = "PURPOSE: Survival following ovarian cancer diagnosis is generally low; understanding factors related to prognosis could be important to optimize treatment. The role of previously diagnosed comorbidities and use of medications for those conditions in relation to prognosis for ovarian cancer patients has not been studied extensively, particularly according to histological subtype.METHODS: Using pooled data from fifteen studies participating in the Ovarian Cancer Association Consortium, we examined the associations between history of hypertension, heart disease, diabetes, and medications taken for these conditions and overall survival (OS) and progression-free survival (PFS) among patients diagnosed with invasive epithelial ovarian carcinoma. We used Cox proportional hazards regression models adjusted for age and stage to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) overall and within strata of histological subtypes.RESULTS: History of diabetes was associated with increased risk of mortality (n = 7,674; HR = 1.12; 95% CI = 1.01-1.25). No significant mortality associations were observed for hypertension (n = 6,482; HR = 0.95; 95% CI = 0.88-1.02) or heart disease (n = 4,252; HR = 1.05; 95% CI = 0.87-1.27). No association of these comorbidities was found with PFS in the overall study population. However, among patients with endometrioid tumors, hypertension was associated with lower risk of progression (n = 339, HR = 0.54; 95% CI = 0.35-0.84). Comorbidity was not associated with OS or PFS for any of the other histological subtypes. Ever use of beta blockers, oral antidiabetic medications, and insulin was associated with increased mortality, HR = 1.20; 95% CI = 1.03-1.40, HR = 1.28; 95% CI = 1.05-1.55, and HR = 1.63; 95% CI = 1.20-2.20, respectively. Ever use of diuretics was inversely associated with mortality, HR = 0.71; 95% CI = 0.53-0.94.CONCLUSIONS: Histories of hypertension, diabetes, and use of diuretics, beta blockers, insulin, and oral antidiabetic medications may influence the survival of ovarian cancer patients. Understanding mechanisms for these observations could provide insight regarding treatment.",

keywords = "Adrenergic beta-Antagonists/therapeutic use, Adult, Aged, Diabetes Mellitus/drug therapy, Disease-Free Survival, Female, Heart Diseases/complications, Humans, Hypertension/complications, Hypoglycemic Agents/therapeutic use, Insulin/therapeutic use, Middle Aged, Ovarian Neoplasms/complications, Risk, Survival Rate",

author = "Minlikeeva, {Albina N} and Freudenheim, {Jo L} and Cannioto, {Rikki A} and Szender, {J Brian} and Eng, {Kevin H} and Francesmary Modugno and Ness, {Roberta B} and LaMonte, {Michael J} and Grace Friel and Segal, {Brahm H} and Kunle Odunsi and Paul Mayor and Emese Zsiros and Barbara Schmalfeldt and R{\"u}diger Klapdor and Thilo Dӧrk and Peter Hillemanns and Kelemen, {Linda E} and Martin Kӧbel and Helen Steed and {de Fazio}, Anna and Jordan, {Susan J} and Nagle, {Christina M} and Risch, {Harvey A} and Rossing, {Mary Anne} and Doherty, {Jennifer A} and Goodman, {Marc T} and Robert Edwards and Keitaro Matsuo and Mika Mizuno and Karlan, {Beth Y} and Kj{\ae}r, {Susanne K} and Estrid H{\o}gdall and Allan Jensen and Schildkraut, {Joellen M} and Terry, {Kathryn L} and Cramer, {Daniel W} and Bandera, {Elisa V} and Paddock, {Lisa E} and Kiemeney, {Lambertus A} and Massuger, {Leon F} and Jolanta Kupryjanczyk and Andrew Berchuck and Jenny Chang-Claude and Brenda Diergaarde and Webb, {Penelope M} and Moysich, {Kirsten B} and {Australian Ovarian Cancer Study Group}",

year = "2017",

month = may,

day = "1",

doi = "10.1007/s10552-017-0867-1",

language = "English",

volume = "28",

pages = "469--486",

journal = "Cancer Causes & Control",

issn = "0957-5243",

publisher = "Springer",

number = "5",

}

TY - JOUR

T1 - History of hypertension, heart disease, and diabetes and ovarian cancer patient survival

T2 - evidence from the ovarian cancer association consortium

AU - Minlikeeva, Albina N

AU - Freudenheim, Jo L

AU - Cannioto, Rikki A

AU - Szender, J Brian

AU - Eng, Kevin H

AU - Modugno, Francesmary

AU - Ness, Roberta B

AU - LaMonte, Michael J

AU - Friel, Grace

AU - Segal, Brahm H

AU - Odunsi, Kunle

AU - Mayor, Paul

AU - Zsiros, Emese

AU - Schmalfeldt, Barbara

AU - Klapdor, Rüdiger

AU - Dӧrk, Thilo

AU - Hillemanns, Peter

AU - Kelemen, Linda E

AU - Kӧbel, Martin

AU - Steed, Helen

AU - de Fazio, Anna

AU - Jordan, Susan J

AU - Nagle, Christina M

AU - Risch, Harvey A

AU - Rossing, Mary Anne

AU - Doherty, Jennifer A

AU - Goodman, Marc T

AU - Edwards, Robert

AU - Matsuo, Keitaro

AU - Mizuno, Mika

AU - Karlan, Beth Y

AU - Kjær, Susanne K

AU - Høgdall, Estrid

AU - Jensen, Allan

AU - Schildkraut, Joellen M

AU - Terry, Kathryn L

AU - Cramer, Daniel W

AU - Bandera, Elisa V

AU - Paddock, Lisa E

AU - Kiemeney, Lambertus A

AU - Massuger, Leon F

AU - Kupryjanczyk, Jolanta

AU - Berchuck, Andrew

AU - Chang-Claude, Jenny

AU - Diergaarde, Brenda

AU - Webb, Penelope M

AU - Moysich, Kirsten B

AU - Australian Ovarian Cancer Study Group

PY - 2017/5/1

Y1 - 2017/5/1

N2 - PURPOSE: Survival following ovarian cancer diagnosis is generally low; understanding factors related to prognosis could be important to optimize treatment. The role of previously diagnosed comorbidities and use of medications for those conditions in relation to prognosis for ovarian cancer patients has not been studied extensively, particularly according to histological subtype.METHODS: Using pooled data from fifteen studies participating in the Ovarian Cancer Association Consortium, we examined the associations between history of hypertension, heart disease, diabetes, and medications taken for these conditions and overall survival (OS) and progression-free survival (PFS) among patients diagnosed with invasive epithelial ovarian carcinoma. We used Cox proportional hazards regression models adjusted for age and stage to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) overall and within strata of histological subtypes.RESULTS: History of diabetes was associated with increased risk of mortality (n = 7,674; HR = 1.12; 95% CI = 1.01-1.25). No significant mortality associations were observed for hypertension (n = 6,482; HR = 0.95; 95% CI = 0.88-1.02) or heart disease (n = 4,252; HR = 1.05; 95% CI = 0.87-1.27). No association of these comorbidities was found with PFS in the overall study population. However, among patients with endometrioid tumors, hypertension was associated with lower risk of progression (n = 339, HR = 0.54; 95% CI = 0.35-0.84). Comorbidity was not associated with OS or PFS for any of the other histological subtypes. Ever use of beta blockers, oral antidiabetic medications, and insulin was associated with increased mortality, HR = 1.20; 95% CI = 1.03-1.40, HR = 1.28; 95% CI = 1.05-1.55, and HR = 1.63; 95% CI = 1.20-2.20, respectively. Ever use of diuretics was inversely associated with mortality, HR = 0.71; 95% CI = 0.53-0.94.CONCLUSIONS: Histories of hypertension, diabetes, and use of diuretics, beta blockers, insulin, and oral antidiabetic medications may influence the survival of ovarian cancer patients. Understanding mechanisms for these observations could provide insight regarding treatment.

AB - PURPOSE: Survival following ovarian cancer diagnosis is generally low; understanding factors related to prognosis could be important to optimize treatment. The role of previously diagnosed comorbidities and use of medications for those conditions in relation to prognosis for ovarian cancer patients has not been studied extensively, particularly according to histological subtype.METHODS: Using pooled data from fifteen studies participating in the Ovarian Cancer Association Consortium, we examined the associations between history of hypertension, heart disease, diabetes, and medications taken for these conditions and overall survival (OS) and progression-free survival (PFS) among patients diagnosed with invasive epithelial ovarian carcinoma. We used Cox proportional hazards regression models adjusted for age and stage to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) overall and within strata of histological subtypes.RESULTS: History of diabetes was associated with increased risk of mortality (n = 7,674; HR = 1.12; 95% CI = 1.01-1.25). No significant mortality associations were observed for hypertension (n = 6,482; HR = 0.95; 95% CI = 0.88-1.02) or heart disease (n = 4,252; HR = 1.05; 95% CI = 0.87-1.27). No association of these comorbidities was found with PFS in the overall study population. However, among patients with endometrioid tumors, hypertension was associated with lower risk of progression (n = 339, HR = 0.54; 95% CI = 0.35-0.84). Comorbidity was not associated with OS or PFS for any of the other histological subtypes. Ever use of beta blockers, oral antidiabetic medications, and insulin was associated with increased mortality, HR = 1.20; 95% CI = 1.03-1.40, HR = 1.28; 95% CI = 1.05-1.55, and HR = 1.63; 95% CI = 1.20-2.20, respectively. Ever use of diuretics was inversely associated with mortality, HR = 0.71; 95% CI = 0.53-0.94.CONCLUSIONS: Histories of hypertension, diabetes, and use of diuretics, beta blockers, insulin, and oral antidiabetic medications may influence the survival of ovarian cancer patients. Understanding mechanisms for these observations could provide insight regarding treatment.

KW - Adrenergic beta-Antagonists/therapeutic use

KW - Adult

KW - Aged

KW - Diabetes Mellitus/drug therapy

KW - Disease-Free Survival

KW - Female

KW - Heart Diseases/complications

KW - Humans

KW - Hypertension/complications

KW - Hypoglycemic Agents/therapeutic use

KW - Insulin/therapeutic use

KW - Middle Aged

KW - Ovarian Neoplasms/complications

KW - Risk

KW - Survival Rate

U2 - 10.1007/s10552-017-0867-1

DO - 10.1007/s10552-017-0867-1

M3 - Journal article

C2 - 28293802

SN - 0957-5243

VL - 28

SP - 469

EP - 486

JO - Cancer Causes & Control

JF - Cancer Causes & Control

IS - 5

ER -

History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this